-
Now that male circumcision has been associated with a lower risk for HIV infection in international observational studies and in three randomized controlled clinical trials, international health officials are looking at options in making it more available to men at risk.
-
The results of the PEARL I and PEARL II studies were published recently in the same issue of the New England Journal of Medicine. Both were well-designed, randomized, controlled, double-blinded studies that assessed the safety and efficacy of ulipristal acetate (UPA) for the treatment of symptomatic uterine fibroids.
-
In this issue: Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
It has been long recognized that thrombocytosis (defined as a platelet count > 450,000/mm3) frequently accompanies the diagnosis of advanced cancer and has been associated with poor outcomes.
-
The authors conducted a double-blind, randomized, controlled trial to determine whether the postoperative use of a levonorgestrel intrauterine system (LNG-IUS) was an effective treatment for chronic pelvic pain in women with endometriosis.
-
-
Managing labor is an art, while the actual delivery process requires the addition of skill and experience. Yet, the decision of which route of delivery to employ may have the greatest impact on outcome. A recent article deals with neonatal morbidity, including an important contributor, intracranial injury, and its association with various forms of operative delivery.
-
In this study, 4957 women aged 67 and older were followed prospectively for up to 15 years. Statistical models were used to calculate the bone mineral density (BMD) testing interval for women with normal BMD and those with mild, moderate, or advanced osteopenia.
-
Almost 75% of respondents to the Contraceptive Technology Update 2011 Contraception Survey say they provide advance provision of emergency contraception (EC).
-
New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.
